Phase 1/2, Open-Label, Dose Escalation, Dose Expansion Study of Menin Inhibitor DSP-5336 in Adult Patients (pts) with Acute Leukemia with and without Mixed-Lineage Leukemia (MLL)-Rearrangement or Nucleophosmin 1 (NPM1) Mutation

Phase 1/2, Open-Label, Dose Escalation, Dose Expansion Study of Menin Inhibitor DSP-5336 in Adult Patients (pts) with Acute Leukemia with and without Mixed-Lineage Leukemia (MLL)-Rearrangement or Nucleophosmin 1 (NPM1) Mutation

Relapsed or refractory acute leukemia (AL) in adults, including acute myelogenous leukemia (AML) and acute lymphocytic leukemia (ALL), still represents a significant unmet need. Once AML or ALL relapses after initial treatment, the prognosis is extremely limited, with median survival

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood 2021-11, Vol.138 (Supplement 1), p.4431-4431
Hauptverfasser: Daver, Naval, Affinito, John, Cai, Hongliang, Dobrowolska, Hanna, Dow, Edward, Eguchi, Ken, Song, Gregory, Stoudemire, Jay, Watanbe, Akinobu, Komarnitsky, Philip
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Relapsed or refractory acute leukemia (AL) in adults, including acute myelogenous leukemia (AML) and acute lymphocytic leukemia (ALL), still represents a significant unmet need. Once AML or ALL relapses after initial treatment, the prognosis is extremely limited, with median survival
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2021-147856